Clinical Trials Directory

Trials / Completed

CompletedNCT00232076

Verification Study of Ciclosporin for Atopic Dermatitis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
20 Years – 64 Years
Healthy volunteers

Summary

To assess the efficacy and safety of oral OL27-400MEPC 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8 weeks to patients with severe adult atopic dermatitis. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

Conditions

Interventions

TypeNameDescription
DRUGciclosporin

Timeline

Start date
2004-05-01
Primary completion
2005-03-01
First posted
2005-10-04
Last updated
2011-11-02

Source: ClinicalTrials.gov record NCT00232076. Inclusion in this directory is not an endorsement.